Denali Therapeutics (DNLI) Profit After Tax (2017 - 2024)
Historic Profit After Tax for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.8 million.
- Denali Therapeutics' Profit After Tax rose 395.07% to -$114.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.8 million, marking a year-over-year decrease of 19111.79%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
- According to the latest figures from Q4 2024, Denali Therapeutics' Profit After Tax is -$114.8 million, which was up 395.07% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' 5-year Profit After Tax high stood at $244.9 million for Q4 2020, and its period low was -$119.5 million during Q4 2023.
- Moreover, its 5-year median value for Profit After Tax was -$79.9 million (2021), whereas its average is -$55.7 million.
- Per our database at Business Quant, Denali Therapeutics' Profit After Tax soared by 55328.09% in 2020 and then tumbled by 15399.96% in 2024.
- Denali Therapeutics' Profit After Tax (Quarter) stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then rose by 3.95% to -$114.8 million in 2024.
- Its last three reported values are -$114.8 million in Q4 2024, -$107.2 million for Q3 2024, and -$99.0 million during Q2 2024.